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OBJECTIVES To evaluate, in a prospective and randomized fashion, the efficacy of a pretreatment with
verapamil (V) in reducing recurrences of atrial fibrillation (AF) after electrical cardioversion
(C).
BACKGROUND The increased vulnerability for AF recurrence is probably due to AF-induced changes in the
electrophysiologic properties of the atria. This electrical remodeling seems to be due to
intracellular calcium overload.
METHODS One hundred seven patients with persistent or chronic AF underwent external and/or internal
C. All patients received oral propafenone (P) (900 mg/day) three days before and during the
entire period of follow-up (three months). In the first group, patients received only the P. In
the second group, in adjunct to P, oral V (240 mg/day) was initiated three days before C and
continued during the follow-up. Finally, in the third group, oral V was administered three
days before and continued only for three days after electrical C.
RESULTS During the three months of follow-up, 23 patients (23.7%) had AF recurrence. Mantel-
Haenszel cumulative chi-square reached a significant level only when comparing AF free
survival curves of group I versus group II and group III (chi-square 5 5.2 and 4, respectively;
p , 0.05). Significantly, 15 (65.2%) AF relapses occurred during the first week after
cardioversion with a higher incidence in group I (10/33 patients, 30.3%) than group II (2/34
patients, 5.9%; p 5 0.01) and group III (3/30 patients, 10%; p 5 0.04).
CONCLUSIONS Six days of oral V administration centered on the C day, combined with P, significantly
reduce the incidence of early recurrences of AF compared with P alone. (J Am Coll Cardiol
1999;34:810–4) © 1999 by the American College of Cardiology
In patients with atrial fibrillation (AF), long-term mainte-
nance of sinus rhythm after successful cardioversion is
difficult, mainly because of a high recurrence rate of AF
within the first month after cardioversion. Recent studies
suggest that an increased vulnerability to AF recurrence is
probably due to AF-induced changes in the electrophysi-
ologic properties of the atria (1–2). This electrical remod-
eling, which has been seen to be completely reversible in
goats within one week after restoration of sinus rhythm (1),
seems to be due to intracellular calcium overload. Admin-
istration of calcium gluconate during rapid atrial pacing in
dogs induced a distinct delay in recovery from electrical
remodeling after cessation of pacing (3), while verapamil
infusion during rapid atrial pacing (3,4) or short episodes of
induced AF (5,6) significantly reduced the electrical remod-
eling of the atria. To date, only one retrospective study (7)
has evaluated the role of intracellular calcium-lowering
drugs in the clinical setting. The aim of our study was to
evaluate in a prospective and randomized fashion the
efficacy of a pretreatment with verapamil in reducing recur-
rences of AF in patients with persistent or chronic AF after
external or internal electrical cardioversion.
METHODS
Patient population. One hundred seven out of 134 con-
secutive patients with persistent or chronic AF (8), referred
to our centers for electrical cardioversion, were enrolled.
Exclusion criteria were: 1) a previous history of sick sinus
syndrome and/or trifascicular block; 2) mean daytime ven-
tricular rate of 60 beats/min and/or 3 s pause during 24-h
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electrocardiogram (ECG) Holter recording; 3) a previous
history of a sustained ventricular arrhythmia, cardiac arrest
or congenital QT syndrome; 4) AF due to reversible causes
(e.g., hyperthyroidism); 5) a history of myocardial infarction
or a revascularization procedure within the previous six
months; 6) a history of thromboembolic events; 7) a left
atrial thrombus diagnosed by transesophageal echocardiog-
raphy obtained the day before cardioversion; 8) major
hepatic or renal dysfunction; 9) signs of severe cardiac or
respiratory insufficiency with a left ventricle ejection fraction
35%; 10) an implanted pacing device.
Study protocol. All patients gave informed written consent
to take part in the study. A detailed clinical examination,
thyroid function tests, chest radiography and transthoracic
and transesophageal echocardiography were routinely per-
formed. Calcium channel blockers, beta-adrenergic antag-
onists and all antiarrhythmic agents, including digitalis or
other drugs depressing atrioventricular node conduction,
were stopped for at least five half-lives and for at least two
months in the case of amiodarone before randomization. All
patients were treated with oral anticoagulation using war-
farin sodium to achieve an international normalized ratio of
2.5 to 3.5 for three weeks before electrical cardioversion.
Three days before cardioversion, patients were randomized
into three groups. All patients received oral propafenone
(900 mg/day) three days before and during the entire period
of follow-up. In the first group, patients received only the
oral propafenone. In the second group, as in adjunct to
propafenone, oral verapamil (240 mg/day) was initiated
three days before electrical cardioversion and both were
continued during the follow-up; finally, in the third group,
oral verapamil (240 mg/day) was administered three days
before and continued for three days after electrical cardio-
version. All patients were followed up for three months.
Clinical examination and 12-lead ECG were scheduled every day
during the three days of hospitalization after cardioversion
and, after hospital discharge, at 1 week, 30 and 90 days.
Electrical cardioversion. During continuous 12-lead
ECG monitoring and heavy sedation with propofol
(2 mg/kg), up to three synchronized external monophasic
shocks (200, 360, 360 J) were delivered to restore sinus
rhythm. A successful cardioversion was defined as a cardio-
version that restored sinus rhythm for at least three beats.
An AF recurrence, after this period, was classified as an
early recurrence on the first day. Patients in whom an initial
attempt of external cardioversion was ineffective, or who had
previously undergone external cardioversion without suc-
cess, underwent internal atrial defibrillation. In these pa-
tients two quadripolar catheters for pacing, sensing and
defibrillation were located in the lateral right atrium and left
pulmonary vein. After sedation with diazepam (10 mg IV
[intravenous]) or heavy sedation with propofol (2 mg/kg),
and during continuous ECG monitoring, shocks were
delivered with a step-up (5, 10, 15, 30 J) protocol until sinus
rhythm was restored. Thereafter, cardiac rhythm was mon-
itored by telemetry for at least 4 h and a 12-lead ECG was
performed at 12, 24 and 36 h after electrical cardioversion.
Patients were generally discharged 36 to 48 h after cardioversion.
Statistical analysis. Continuous variables are expressed as
mean 6 standard deviation. The Fisher exact test was used
to compare proportions. Atrial fibrillation-free survival data
from the three groups were analyzed by the Mantel-
Haenszel cumulative chi-square test. Clinical data from the
three study groups were compared using a Student t test
with Bonferroni correction for multiple comparisons.
RESULTS
Patient characteristics. There was no significant difference
in any clinical characteristics among the three groups, as
summarized in Table 1. The duration of AF was at least of
two months. In seven (6.5%) patients, sinus rhythm was
documented at the time of cardioversion (one in group I,
three in group II and three in group III). There was no
difference in the incidence of sinus rhythm restoration
between patients receiving propafenone alone or combined
with verapamil (2.9% vs. 8.2%, p 5 NS). Eight (8%)
patients were dropped from the follow-up because of
pharmacological side effects (Table 2). However, only the
three patients who stopped the pharmacological therapy
before cardioversion were not enrolled. There was no
difference in the incidence of complications between pa-
tients who received propafenone alone or combined with
verapamil (5.9% vs. 8.2%, p 5 NS). Of the remaining 97
patients who entered follow-up, 33 were randomized in the
group I, 34 in group II and 30 in group III.
Electrical cardioversion. All patients successfully under-
went electrical cardioversion. In 53 out of 67 (79%) patients,
external cardioversion restored sinus rhythm with a mean of
2.0 6 0.8 shocks and a mean cumulative energy of 567 6
304 J. In 44/44 (100%) patients, successful internal cardio-
version was performed with a mean of 2.0 6 0.9 shocks at
a mean energy of 10.8 6 6.4 J.
AF recurrences. During the three months of follow-up, 23
patients (23.7%) had AF recurrence. No patients developed
atrial flutter during the follow-up. Figure 1 shows AF-free
survival during the follow-up period of each group. Mantel-
Haenszel cumulative chi-square among the three curves
reached a significant level when comparing group I with
groups II and III (chi-square 5 5.2 and 4, respectively; p ,
0.05), but not when comparing group II with group III.
Significantly, 15 (65.2%) AF relapses occurred during the
first week after cardioversion with a higher incidence in
Abbreviations and Acronyms
AF 5 atrial fibrillation
ECG 5 electrocardiogram
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group I (10/33 patients, 30.3%) than in groups II (2/34
patients, 5.9%; p 5 0.01) and III (3/30 patients, 10%; p 5
0.04). The remaining eight relapses were distributed among
the three groups without significant statistical difference
(three in group I, three in group II and two in group III).
The overall incidence of AF recurrences was higher in group
I than in group II (13 vs. 5, p 5 0.02) and group III (13 vs.
5, p 5 0.04), whereas there was no difference between group
II and III. All but two episodes of AF recurrences were
persistent and required a new electrical cardioversion; in one
patient in group I and one in group II, the AF relapse lasted
8 and 24 h, respectively.
DISCUSSION
To our knowledge, this is the first study to demonstrate, in
a prospective and randomized fashion, the efficacy of an oral
pretreatment with verapamil, associated with propafenone,
in reducing early recurrences of AF after external or internal
electrical cardioversion. The time course of AF relapses,
with 68.4% of overall AF recurrence within seven days,
confirms that recovery from electrical remodeling of the
atria occurs within few days, and might explain why the
reduction of early AF recurrences resulted in overall AF
recurrence reduction.
Electrical remodeling of the atria. The clinical observa-
tions that paroxysmal AF can progress to chronic AF (9)
and that the incidence of successful restoration and main-
tenance of sinus rhythm is higher in patients with recent-
onset AF (10) have suggested that AF might be self-
perpetuating. Recently, several invasive studies, performed
both in animals and in humans (1–6,11,12), have shown
that AF begets AF, and that this is due to an electrical
remodeling of the atria, which consists of shortening of
atrial refractory periods, loss of the physiologic rate-
dependent adaptation of the refractory period and short
duration of monophasic potential. Although the exact
mechanisms by which these electrophysiologic changes
occur are largely unknown, reduction of the electrical
remodeling process might prevent or diminish the negative
effects of the duration of AF on the success rate of
Figure 1. AF-free survival data during follow-up period of each
group. Mantel-Haenszel cumulative chi-square among the three
curves reached a significant level when comparing group I with
group II and III (chi-square 5 5.2 and 4, respectively; p , 0.05),
but not when comparing group II with group III.
Table 1. Clinical Characteristics
Group I
(34)
Group II
(38)
Group III
(35) p
Age (yrs) 63.7 6 10 62.9 6 10.5 63.8 6 11.4 NS
Gender (M/F) 20/14 23/15 21/14 NS
LA diameter (mm) 45.8 6 6.6 45.6 6 5.9 45.8 6 6.2 NS
LVEF (%) 49.1 6 9.3 49.8 6 8.6 49.5 6 9.2 NS
Duration AF (months) 17.4 6 20.8 17.1 6 22 16.5 6 21.9 NS
Previous AF episodes 4.9 6 2.7 4.8 6 2.6 4.5 6 2.2 NS
Previous AA drugs 3.2 6 0.9 3.1 6 0.8 3.3 6 1 NS
Heart disease NS
None 4 5 3 NS
Hypertension 17 19 17 NS
CHD 7 7 8 NS
Valvular 4 5 6 NS
DCM 2 2 1 NS
AA 5 antiarrhythmic; CHD 5 coronary heart disease; DCM 5 dilated cardiomyopathy; LA 5 left atrium; LVEF 5 left
ventricular ejection fraction.
Table 2. Complications
Patient
No. Group Side Effect Time
4 III Bradycardia 36 h after R, before CV
11 I Bradycardia 1 h after CV
15 III Bradycardia 60 h after R, before CV
41 II II degree AV block 168 h after CV
57 II Low pressure 36 h after R, before CV
74 I I degree AV block 6 h after CV
97 III II degree AV block 24 h after CV
106 II Bradycardia 120 h after CV
CV 5 cardioversion; R 5 randomization and pretreatment beginning.
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cardioversion and might reduce early AF recurrences after
successful cardioversion. In our study, most AF recurrences
(68.4%) occurred in the first week after cardioversion, while
the remaining ones were progressively less frequent during
the three-month follow-up period (Fig. 1). A period of
seven days might be the clinical representation of recovery
from electrical remodeling of the atria in patients with AF
lasting at least two months. Our data are in agreement with
Tielman et al. (7), who analyzed the moment of recurrence
of AF after successful electrical cardioversion with a time
resolution of one day, and found a relatively high incidence
of AF recurrences during the first five days after cardiover-
sion. Moreover, in goats with pacing-induced chronic AF,
Wijffels et al. (1) showed that electrical remodeling of the
atria was completely reversible within one week after resto-
ration of sinus rhythm. These data should focus our atten-
tion to reduce early recurrences of AF in order to reduce the
overall incidence of AF recurrences.
Role of intracellular calcium-lowering drugs. Previous
studies have shown that initiation of antiarrhythmic drugs
before electrical cardioversion decreases the recurrence of
AF (13–15). The finding that recovery from the electrical
remodeling of the atria is critical in the restoration and
maintenance of sinus rhythm suggests the use of drugs that
could affect this recovering. Recent animal studies have
suggested that intracellular calcium plays a pivotal role in
the mechanism of the electrical remodeling of the atria
(4,5). In goats, pacing-induced electrical remodeling was
significantly reduced by the administration of verapamil
during arrhythmia. As a result, after cessation of rapid atrial
pacing, the atrial refractory period returned sooner to its
control value (5). In contrast, rapid atrial pacing during
hypercalcemia in dogs resulted in a distinct delay of recovery
from electrical remodeling (4). Yu at al. (6) investigated the
effect of atrial rate and antiarrhythmic drugs on the effective
refractory period shortening induced by 10 min of tachy-
cardia (fast atrial pacing and AF). They found that the atrial
effective refractory period shortened after conversion of AF
and that this shortening was attenuated after verapamil
infusion but was unchanged after infusion of the other
antiarrhythmic drugs (procainamide, propafenone, pro-
panolol, dl-sotalol and amiodarone). In a retrospective
analysis of 61 patients cardioverted for chronic AF, Tielman
et al. (7) recently documented that the use of intracellular
calcium-lowering drugs during AF was the only significant
variable related to the maintenance of sinus rhythm after
cardioversion (p 5 0.03). To date, our study is the only one
to compare, in a prospective and randomized fashion, a
pretreatment with a class IC antiarrhythmic drug alone or
combined with verapamil in patients undergoing electrical
cardioversion. The higher incidence of AF recurrences in
group I than in groups II and III (Fig. 1) confirms the data
of Tielman et al. (7) and laboratory observations (4–6)
suggesting that intracellular calcium-lowering drugs reduce
electrical remodeling, which may in turn lead to a more
rapid recovery from electrical remodeling after cardiover-
sion. The lack of evidence of a higher efficacy of long-term
therapy with verapamil (group II) compared with a short-
term therapy (group III) supports the hypothesis that the
recovery from electrical remodeling occurs in a few days and
that after this period intracellular calcium-lowering drugs
might have a marginal role in preventing AF recurrences.
Study limitations. The study has several potential limita-
tions: 1) Although a faster recovery from electrical remod-
eling has been proposed as the mechanism by which calcium
antagonists reduce early AF recurrences, the atrial effective
refractory period has been measured only in some patients
and we cannot assess whether calcium antagonists actually
lengthen the atrial effective refractory period more than class
IC antiarrhythmic drugs alone; 2) The moment of AF
recurrence was documented at 1, 2, 3, 7, 30 and 90 days.
Continuous telemetric ECG monitoring could better assess
the exact time of AF relapses. However, previous studies (7)
have already demonstrated a relatively high incidence of AF
recurrences during the first five days after cardioversion; 3)
The combined use of propafenone and verapamil, at a high
dosage, raises the problem of the side effects. In our study
eight (7.4%) patients were dropped because of pharmaco-
logic side effects. However, because the verapamil regime,
starting three days before and lasting three days after
cardioversion, is undertaken by in-hospital patients, the
clinical impact of side effects is probably reduced; 4)
Although the results about AF recurrences were statistically
significant, the number of patients included was small
(about 30 per group). In a wider study, the difference in the
rate of sinus rhythm restoration before cardioversion, com-
plication, kind of AF recurrence (paroxysmal or persistent),
number of previous episodes of AF, number of previous
(failed) antiarrhythmic drugs used or any other clinical
characteristics might reach a significant level.
Conclusions. The administration of oral verapamil com-
bined with propafenone for six days, centered around the
cardioversion day, significantly reduces the incidence of
early AF recurrences compared with oral propafenone alone.
The time course of AF relapses and the lack of benefits of
long-term therapy with verapamil strongly support the
hypothesis that calcium antagonists only facilitate recovery
from electrical remodeling.
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